XOMA Royalty (XOMA) Operating Expenses (2011 - 2026)
XOMA Royalty (XOMA) reported Operating Expenses of $12.8 million for Q1 2026, up 28.2% on a YoY basis from $10.0 million in Q1 2025, and up 10.57% sequentially from $11.6 million in Q4 2025.
XOMA Royalty (XOMA) Operating Expenses (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 16 years of Operating Expenses data on file, last reported at $12.8 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 28.2% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $32.9 million (down 52.97% YoY), and the FY2025 full-year result was $40.8 million, down 40.46% from the prior year.
- Operating Expenses rose to $12.8 million in Q1 2026, from $11.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $22.8 million in Q3 2024 to a low of $4.8 million in Q3 2022.
- A 5-year average of $11.3 million and a median of $9.3 million in 2025 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses soared 245.13% in 2024 and sank 59.72% in 2025, its largest moves.
- Tracing XOMA's Operating Expenses over 5 years: stood at $7.7 million in 2022, then jumped by 182.84% to $21.8 million in 2023, then dropped by 26.65% to $16.0 million in 2024, then declined by 27.51% to $11.6 million in 2025, then climbed by 10.57% to $12.8 million in 2026.
- Business Quant data shows XOMA's Operating Expenses at $12.8 million in Q1 2026, $11.6 million in Q4 2025, and $8.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.10 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -919.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 445.22 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 12.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.80 Mn |
| Dec 31, 2025 | 11.58 Mn |
| Jun 30, 2025 | 8.53 Mn |
| Mar 31, 2025 | 9.98 Mn |
| Dec 31, 2024 | 15.97 Mn |
| Sep 30, 2024 | 22.84 Mn |
| Jun 30, 2024 | 21.17 Mn |
| Mar 31, 2024 | 8.49 Mn |
| Dec 31, 2023 | 21.77 Mn |
| Sep 30, 2023 | 6.62 Mn |
| Jun 30, 2023 | 7.62 Mn |
| Mar 31, 2023 | 10.61 Mn |
| Dec 31, 2022 | 7.70 Mn |
| Sep 30, 2022 | 4.82 Mn |
| Jun 30, 2022 | 5.75 Mn |
| Mar 31, 2022 | 5.17 Mn |
| Dec 31, 2021 | 5.58 Mn |
| Sep 30, 2021 | 4.29 Mn |
| Jun 30, 2021 | 3.97 Mn |
| Mar 31, 2021 | 6.80 Mn |